Joshua Lehrer-Graiwer - 17 Sep 2026 Form 3 Insider Report for LISATA THERAPEUTICS, INC. (LSTA)

Reporting relationship: President & COO
Issuer ticker: LSTA
Reported as of: 17 Sep 2026
Net transaction value: $0
SEC form: 3
Accepted by SEC: 28 Sep 2026, 21:29:40 UTC
Prior SEC filing: 01 May 2026
Source filing: View source filing
Reporting owner signature: /s/ James Nisco, Attorney-in-Fact for Joshua Lehrer-Graiwer

Filing notes and source

Key filing fact

Joshua Lehrer-Graiwer filed Form 3 for LISATA THERAPEUTICS, INC. (LSTA) on 28 Sep 2026.

Key facts

This page summarizes Joshua Lehrer-Graiwer's Form 3 filing for LISATA THERAPEUTICS, INC. (LSTA).
0 reported transactions and 8 derivative rows are listed below.
Accepted by SEC: 28 Sep 2026, 21:29.

Change

Previous filing in this sequence was filed on 01 May 2026.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Official SEC source

Ownership activity is grounded in SEC Form 3 disclosures.

View source filing

Reporting Owners (1)

CIK 0001789673 Primary reporting owner

Lehrer-Graiwer Joshua

Relationship: President & COO
Address: C/O LISATA THERAPEUTICS, INC., P.O. BOX 173, LIBERTY CORNER
Signature: /s/ James Nisco, Attorney-in-Fact for Joshua Lehrer-Graiwer
Signature date: 28 Sep 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

LSTA holding

Common Stock

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after: 21,548
Date: 17 Sep 2026
Ownership: Direct
Footnotes: F1, F2

LSTA holding

Common Stock

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after: 6,260
Date: 17 Sep 2026
Ownership: See footnote
Footnotes: F1, F2, F3

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

LSTA holding Derivative

Series C Non-Voting Convertible Preferred Stock

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after
Date: 17 Sep 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 2,540,002
Exercise price
Footnotes: F1, F2, F4

LSTA holding Derivative

Series C Non-Voting Convertible Preferred Stock

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after
Date: 17 Sep 2026
Ownership: See footnote
Underlying class: Common Stock
Underlying amount: 737,919
Exercise price
Footnotes: F1, F2, F3, F4

LSTA holding Derivative

Stock Option (right to buy)

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after
Date: 17 Sep 2026
Ownership: Direct
Underlying class: Series C Non-Voting Convertible Preferred Stock
Underlying amount: 2,464
Exercise price: $318.85
Footnotes: F4, F5

LSTA holding Derivative

Stock Option (right to buy)

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after
Date: 17 Sep 2026
Ownership: Direct
Underlying class: Series C Non-Voting Convertible Preferred Stock
Underlying amount: 2,930
Exercise price: $318.85
Footnotes: F4, F5

LSTA holding Derivative

Stock Option (right to buy)

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after
Date: 17 Sep 2026
Ownership: Direct
Underlying class: Series C Non-Voting Convertible Preferred Stock
Underlying amount: 713
Exercise price: $709.69
Footnotes: F4, F5, F6, F7

LSTA holding Derivative

Stock Option (right to buy)

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after
Date: 17 Sep 2026
Ownership: Direct
Underlying class: Series C Non-Voting Convertible Preferred Stock
Underlying amount: 762
Exercise price: $709.69
Footnotes: F4, F5, F8, F9

LSTA holding Derivative

Stock Option (right to buy)

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after
Date: 17 Sep 2026
Ownership: Direct
Underlying class: Series C Non-Voting Convertible Preferred Stock
Underlying amount: 59
Exercise price: $545.13
Footnotes: F4, F5, F6, F7

LSTA holding Derivative

Stock Option (right to buy)

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after
Date: 17 Sep 2026
Ownership: Direct
Underlying class: Series C Non-Voting Convertible Preferred Stock
Underlying amount: 63
Exercise price: $545.13
Footnotes: F4, F5, F8, F9

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 9 footnotes

Footnote F1

The reported shares of Common Stock and shares of Common Stock underlying shares of Series C Non-Voting Convertible Preferred Stock represent shares received in exchange for 3,400,043 shares of common stock of Marea Therapeutics, Inc. ("Marea") in connection with the Issuer's merger (the "Merger") with Marea pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated September 17, 2026, by and among the Issuer, Marea, Mariner Merger Sub I, Inc. and Mariner Merger Sub II, LLC. Under the terms of the Merger Agreement, at the effective time of the Merger, each outstanding share of Marea's common stock was cancelled and converted into the right to receive 0.9723 shares of Common Stock or, in lieu thereof, 0.0009723 shares of Series C Non-Voting Convertible Preferred Stock (representing 0.9723 shares of Common Stock on an as-converted basis) (the "Preferred Share Exchange Ratio"). A portion of the reported shares of Common Stock and Series C Non-Voting Convertible

Footnote F2

(continued from Footnote 1) Preferred Stock are subject to an Issuer right of repurchase that lapses in accordance with time- or milestone-based vesting conditions set forth in the applicable stock purchase agreements.

Footnote F3

The shares are held by the Lehrer Family Irrevocable GST Exempt Trust U/A/D November 21, 2025.

Footnote F4

Each share of Series C Non-Voting Convertible Preferred Stock will automatically convert into 1,000 shares of Common Stock upon the approval of such conversion by the Issuer's stockholders in accordance with the rules of the Nasdaq Stock Market LLC, subject to a beneficial ownership limitation to be established by the holder of between 4.9% and 19.99% of the outstanding Common Stock. The Series C Non-Voting Convertible Preferred Stock does not have a conversion price and has no expiration date.

Footnote F5

Represents options to purchase shares of Marea common stock assumed by the Issuer at the effective time of the Merger. At the effective time of the Merger, each outstanding option to purchase Marea common stock was assumed by the Issuer and adjusted to reflect the right to purchase a number of shares of Series C Non-Voting Convertible Preferred Stock equal to the Preferred Share Exchange Ratio, with a corresponding adjustment to the applicable exercise price per share. See Footnotes 1, 2 and 4.

Footnote F6

The option vests as to 100% of the underlying shares upon a Valuation Determination Event in which the Valuation Per Share is greater than $5.01 (the "Target Price"), subject to the optionee remaining in a Service Relationship through such Valuation Determination Event (or, if earlier, termination of the optionee's Service Relationship without Cause within 60 days of the Valuation Determination Event). A "Valuation Determination Event" means the closing of a Sale Event, an initial public offering, a reverse merger or SPAC business combination, an exchange listing without an underwritten offering, or the first trading day on which the 40-trading-day trailing average closing price of the Company's common stock equals or exceeds the Target Price. "Valuation Per Share" means, as applicable, the Sale Price in a Sale Event, the IPO price, the implied per-share consideration in a reverse merger/business combination, the closing price on first listing, or the trailing average described above.

Footnote F7

(continued from Footnote 6) The Target Price is subject to adjustment for stock splits, dividends, combinations or similar recapitalizations. Capitalized terms not otherwise defined have the meanings given in the Company's equity incentive plan and the applicable award agreement.

Footnote F8

The option vests as to 100% of the underlying shares upon a Valuation Determination Event in which the Valuation Per Share is greater than $8.35 (the "Target Price"), subject to the optionee remaining in a Service Relationship through such Valuation Determination Event (or, if earlier, termination of the optionee's Service Relationship without Cause within 60 days of the Valuation Determination Event). A "Valuation Determination Event" means the closing of a Sale Event, an initial public offering, a reverse merger or SPAC business combination, an exchange listing without an underwritten offering, or the first trading day on which the 40-trading-day trailing average closing price of the Company's common stock equals or exceeds the Target Price. "Valuation Per Share" means, as applicable, the Sale Price in a Sale Event, the IPO price, the implied per-share consideration in a reverse merger/business combination, the

Footnote F9

(continued from Footnote 8) closing price on first listing, or the trailing average described above. The Target Price is subject to adjustment for stock splits, dividends, combinations or similar recapitalizations. Capitalized terms not otherwise defined have the meanings given in the Company's equity incentive plan and the applicable award agreement.

SEC remarks

Power of Attorney attached as Exhibit 24.

We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. to update or revoke optional consent for future visits. For more information, see our Privacy Policy .